Stem cell therapies benefit Alport syndrome

Area of Science:

• Nephrology
• Regenerative Medicine
• Genetics

Background:

• Alport syndrome is a genetic kidney disease caused by defects in type IV collagen.
• The glomerular basement membrane is crucial for kidney filtration and is affected in Alport syndrome.
• Col4A3 knockout mice serve as a model for Alport syndrome, displaying progressive renal dysfunction.

Purpose of the Study:

• To investigate the potential of cell-based therapies, independent of transplantation, for treating Alport syndrome.
• To evaluate the efficacy of bone marrow-derived cells, blood transfusion, and stem cells in a mouse model of Alport syndrome.
• To determine if these therapies can repair the defective glomerular basement membrane and improve renal function.

Main Methods:

• Infusion of wild-type bone marrow-derived cells into unconditioned Col4A3 knockout mice.
• Transfusion of unfractionated wild-type blood into unconditioned Col4A3 knockout mice.
• Injection of mouse and human embryonic stem cells into Col4A3 knockout mice.

Main Results:

• Cell-based therapies significantly improved renal histology and function in late-stage Alport syndrome mice.
• Blood transfusion improved the renal phenotype and significantly increased survival rates.
• All tested treatments led to de novo expression of the alpha3(IV) chain, restoring glomerular basement membrane architecture.

Conclusions:

• Cell-based therapies, including bone marrow cells, blood, and stem cells, are effective in ameliorating Alport syndrome in a mouse model.
• These non-transplant strategies offer a potential new avenue for treating Alport syndrome.
• The restoration of alpha3(IV) chain expression is a key mechanism underlying the therapeutic benefits.